



PPD Recognized for Excellence in Clinical Research in CRO Leadership Awards

May 1, 2019

Honored for capabilities, compatibility and expertise provided to biopharmaceutical companies

WILMINGTON, N.C., (May 1, 2019) – Pharmaceutical Product Development, LLC ([PPD](#)) has been recognized for excellence in clinical research for the eighth consecutive year by pharmaceutical and biotech executives surveyed for [Life Science Leader](#) magazine's [2019 CRO Leadership Awards](#).

PPD earned honors in three distinct categories of clinical research, including for its capabilities, compatibility and expertise. The recognition is based on survey responses from biopharmaceutical industry leaders responsible for making or influencing decisions to collaborate with contract research organizations (CROs) on clinical development programs.

In addition, based on data from a separate market survey of pharma companies, PPD was recognized with an individual attribute award for providing clients with robust data analytics technology to inform decision-making in clinical research.

"At PPD, we are committed to accelerating our customers' promising medicines from early development through regulatory approval and market access by generating evidence to demonstrate effectiveness, safety and value," said David Simmons, chairman and CEO of PPD. "We leverage data analytics, patient-centered strategies and the passion of our people for improving health. Their talent, ingenuity and commitment are our formula for extraordinary results. Our clients can rely on us for quality performance, continual innovation and trusted partnership."

The [Life Science Leader](#) 2019 CRO Leadership Awards were based on surveys, encompassing 27 performance metrics, conducted by [Industry Standard Research](#), a full-service pharmaceutical market research firm, to help the publication assess the performance of CROs.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 48 countries and more than 21,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.

PPD Contacts

Media:

Randy Buckwalter

[+1 919 456 4425](tel:+19194564425)

randy.buckwalter@ppdi.com

Investors:

Nate Speicher

[+1 910 558 6783](tel:+19105586783)

nate.speicher@ppdi.com